JP2017506073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017506073A5 JP2017506073A5 JP2016549801A JP2016549801A JP2017506073A5 JP 2017506073 A5 JP2017506073 A5 JP 2017506073A5 JP 2016549801 A JP2016549801 A JP 2016549801A JP 2016549801 A JP2016549801 A JP 2016549801A JP 2017506073 A5 JP2017506073 A5 JP 2017506073A5
- Authority
- JP
- Japan
- Prior art keywords
- standard
- epitope
- amount
- library
- histone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001623 Nucleosomes Anatomy 0.000 claims description 62
- 108010047956 Nucleosomes Proteins 0.000 claims description 62
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 31
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- 210000003483 Chromatin Anatomy 0.000 claims description 11
- 108010077544 Chromatin Proteins 0.000 claims description 11
- 102000004965 antibodies Human genes 0.000 claims description 9
- 108090001123 antibodies Proteins 0.000 claims description 9
- 230000004481 post-translational protein modification Effects 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 8
- 210000004027 cells Anatomy 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 6
- 108010033040 Histones Proteins 0.000 claims description 6
- 102000006947 Histones Human genes 0.000 claims description 6
- 235000009697 arginine Nutrition 0.000 claims description 6
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 6
- 238000007069 methylation reaction Methods 0.000 claims description 6
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- 238000006640 acetylation reaction Methods 0.000 claims description 4
- 229960003121 arginine Drugs 0.000 claims description 4
- 239000007850 fluorescent dye Substances 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229960005261 Aspartic Acid Drugs 0.000 claims description 2
- 229960002989 Glutamic Acid Drugs 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- 238000000376 autoradiography Methods 0.000 claims description 2
- 238000010614 crotonylation reaction Methods 0.000 claims description 2
- 238000001215 fluorescent labelling Methods 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 238000009396 hybridization Methods 0.000 claims description 2
- 238000009830 intercalation Methods 0.000 claims description 2
- 238000007481 next generation sequencing Methods 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 230000003287 optical Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 230000000865 phosphorylative Effects 0.000 claims description 2
- 230000010741 protein sumoylation Effects 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 238000010798 ubiquitination Methods 0.000 claims description 2
- 201000010874 syndrome Diseases 0.000 claims 5
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 206010018338 Glioma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 229920000023 polynucleotide Polymers 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 208000007636 ATR-X syndrome Diseases 0.000 claims 1
- 206010000496 Acne Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000004064 Acoustic Neuroma Diseases 0.000 claims 1
- 208000009956 Adenocarcinoma Diseases 0.000 claims 1
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 241000606646 Anaplasma Species 0.000 claims 1
- 208000009575 Angelman Syndrome Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 claims 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010004938 Bipolar disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100019361 CDKN1C Human genes 0.000 claims 1
- 101710022309 CDKN1C Proteins 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 208000006990 Cholangiocarcinoma Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 201000009343 Cornelia de Lange syndrome Diseases 0.000 claims 1
- 208000009798 Craniopharyngioma Diseases 0.000 claims 1
- 206010011401 Crohn's disease Diseases 0.000 claims 1
- 208000003471 De Lange Syndrome Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 210000002889 Endothelial Cells Anatomy 0.000 claims 1
- 206010014967 Ependymoma Diseases 0.000 claims 1
- 208000002409 Gliosarcoma Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 229940037467 Helicobacter pylori Drugs 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 201000001971 Huntington's disease Diseases 0.000 claims 1
- 208000007367 Kabuki syndrome Diseases 0.000 claims 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims 1
- 206010024190 Leiomyosarcomas Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010024627 Liposarcoma Diseases 0.000 claims 1
- 241000186779 Listeria monocytogenes Species 0.000 claims 1
- 229940115931 Listeria monocytogenes Drugs 0.000 claims 1
- 206010025224 Lymphangiosarcomas Diseases 0.000 claims 1
- 102100014726 MECP2 Human genes 0.000 claims 1
- 101700029603 MECP2 Proteins 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 208000007054 Medullary Carcinoma Diseases 0.000 claims 1
- 206010027191 Meningioma Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000009091 Myxoma Diseases 0.000 claims 1
- 208000001611 Myxosarcoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001715 Osteoblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 206010061536 Parkinson's disease Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 210000004560 Pineal Gland Anatomy 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 241000242680 Schistosoma mansoni Species 0.000 claims 1
- 210000001732 Sebaceous Glands Anatomy 0.000 claims 1
- 241000607762 Shigella flexneri Species 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 208000008383 Wilms Tumor Diseases 0.000 claims 1
- 210000001766 X Chromosome Anatomy 0.000 claims 1
- 201000001256 adenosarcoma Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000006288 alpha thalassemia Diseases 0.000 claims 1
- 201000002434 alpha thalassemia-X-linked intellectual disability syndrome Diseases 0.000 claims 1
- 201000003076 angiosarcoma Diseases 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 201000002055 autistic disease Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000009047 chordoma Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 201000003066 diffuse scleroderma Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 201000009051 embryonal carcinoma Diseases 0.000 claims 1
- 230000003511 endothelial Effects 0.000 claims 1
- 201000008808 fibrosarcoma Diseases 0.000 claims 1
- 201000010238 heart disease Diseases 0.000 claims 1
- 201000002222 hemangioblastoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 201000006512 mast cell neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000010133 oligodendroglioma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 201000008006 pharynx cancer Diseases 0.000 claims 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000582 retinoblastoma Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 201000010208 seminoma Diseases 0.000 claims 1
- 201000010965 sweat gland carcinoma Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000006704 ulcerative colitis Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 230000027455 binding Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 238000001114 immunoprecipitation Methods 0.000 description 10
- 238000002487 chromatin immunoprecipitation Methods 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 102000031025 DNA-Binding Proteins Human genes 0.000 description 4
- 108091000102 DNA-Binding Proteins Proteins 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 238000010379 pull-down assay Methods 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003855 Cell Nucleus Anatomy 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000005298 paramagnetic Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]OC(=O)C([H])(N([H])*)C([H])([H])O[H] 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Description
æ¬çºæã®äžæ
æ§ã«ãããŠã¯ããã«ããŠã³ã¢ãã»ã€ã®çµæãæ£æçåäœã®æ£æçã¹ã±ãŒã«ãã絶察çåäœã®æšæºåã¹ã±ãŒã«ã«å€æããããŒã¿è§£éã®æ£ç¢ºããæ¹åããæ¹æ³ããããæ¬çºæã®äžå®æœåœ¢æ
ã«ãããŠã¯ãæšæºã¯ãçéœæ§ãšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããé¢é£ã®ç¿»èš³åŸä¿®é£Ÿãå«ããã¹ãã³ã®ãããªãå°ãªããšãïŒã€ã®ãåæ§æããããéºäŒåçµã¿æãã®ãååæã®ãåã³ïŒåã¯ãå€ç°ãå«ãçµåèçœè³ªãå«ãã奜é©ãªå®æœåœ¢æ
ã«ãããŠã¯ãæšæºã¯ãåæ§æããããéºäŒåçµã¿æãã®ãååæã®ãåã³ïŒåã¯ãå€ç°ãå«ãçµåèçœè³ªã«çµåããããŒã³ãŒãååãå«ããåãã¿ã€ãã®å€ãã®æšæºã¯æšæºãæ§æããŠããããç°ãªãã¿ã€ãã®å€ãã®æšæºãæšæºãæ§æããŠãããããæšæºãã¯äŸãã°è€æ°ã®ãã¹ãã³âåãã¿ã€ãã®ããŒã³ãŒãååã§ãããä»ã®å®æœåœ¢æ
ã«ãããŠã¯ãäŸãã°æšæºãã©ã€ãã©ãªã«ããŒããããç°ãªãæ¿åºŠããããã瀺ãå€ãã®ç°ãªãããŒã³ãŒãååãå«ããã¹ãã³âããŒã³ãŒãååãå«ãã
æ¬çºæã®ä»ã®æ
æ§ã«ãããŠã¯ãåäœçœ®ã§ã®åœéœæ§åã³çéœæ§ãšãããŒãã®ãã«ããŠã³å¹çã¯ãäžçµã®æšæºãçšããŠå®éãããããŒã¿è§£éã®æ£ç¢ºããæ¹åããŠãããäžå®æœåœ¢æ
ã«ãããŠã¯ãäžçµã®æšæºã¯ãçéœæ§ãšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµååãæããå°ãªããšãïŒã€ã®ãåæ§æããããååæã®ãåã¯ãå€ç°ãå«ãçµåèçœè³ªãåã³ãåœéœæ§ãšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµååãæããå°ãªããšãïŒã€ã®ãååæã®ãåã¯ãå€ç°ãå«ãçµåèçœè³ªãå«ããåèšã®äžçµã®æšæºã®äœ¿çšã¯ãåäœçœ®ã§ã®åœéœæ§åã³çéœæ§ãšãããŒãã®æ°ãå®éããããšãã§ããããããã«ããŠã³ã¢ãã»ã€ã®çµ¶å¯Ÿçå®éåãæ¹åãããéœæ§çäžçãæ¢ã«ç®åºãããŠãããããåäœçœ®ã§ã®åœéœæ§åã³çéœæ§ãšãããŒãã®æ°ã®ç¥èã¯ããŒã¿åæãæ¹åãããããä¿¡é Œã¬ãã«ã§ã®ãšãããŒãã®æå°æ°ã®è©äŸ¡ãå»çç蚺æåã³èª¿æ»ãšããŠã®ãã®ãããªäœ¿çšã«ãšã£ãŠã¯éèŠãªçéœæ§ãèæ
®ãåŸããããéœæ§çäžçã®ç¥èã¯ããŒã¿åæãæ¹åããã
æ¬çºæã®ä»ã®æ
æ§ã«ãããŠã¯ãæ¬çºæã¯ãã¯ãããã³å
ç«æ²éã¢ãã»ã€ã«ãããçéœæ§ãšãããŒãåã³äžçµã®æšæºã®å Žåã«ãããŠã¯åœéœæ§ãšãããŒãã®çµ¶å¯Ÿçå®éåã®ããã«æšæºåã¯äžçµã®æšæºåã³ïŒã€ä»¥äžã®èŠªåæ§è©Šè¬ãå«ãããããæäŸãããæ¬çºæã®ä»ã®æ
æ§ã«ãããŠã¯ãæ¬çºæã¯ãè€æ°ã®è©Šæã«ããã£ãŠãã«ããŠã³ã¢ãã»ã€çµæãæ¯èŒããæ¹æ³ãæäŸããã
ä»ã®æ
æ§ã«ãããŠã¯ãæ¬çºæã¯ã现èã®ã¯ãããã³ã«ãããã²ãã éºäŒå座ã§ã®ã³ã¢ãã¹ãã³ã®ç¬¬ïŒãšãããŒãã®å¯åºŠã枬å®ããæ¹æ³ãæäŸããããã®æ¹æ³ã¯ã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã®ã©ã€ãã©ãªã調補ããå·¥çšãåããåèšã©ã€ãã©ãªã¯ã第ïŒãšãããŒããæããã³ã¢ãã¹ãã³ãå«ããã¯ã¬ãªãœãŒã ãå«ã¿ãåã³ãåèšã²ãã éºäŒå座ã瀺ããã¯ã¬ãªããé
åãå«ããæšæºã¯ããŒãã©ã€ãã©ãªãäœæããããã«ã©ã€ãã©ãªã«æ·»å ãããåèšæšæºã¯ãïŒïœïŒç¬¬ïŒãšãããŒããæããæšæºãã¹ãã³åã¯æšæºãã¹ãã³ãã©ã°ã¡ã³ããåã³ãïŒïœïœïŒããŒã³ãŒãååã«çµåããæšæºãã¯ã¬ãªããé
åãå«ãæšæºååãå«ãåæ§æãã¯ã¬ãªãœãŒã ãå«ã¿ãåèšæšæºãã¹ãã³åã¯æšæºãã¹ãã³ãã©ã°ã¡ã³ãåã³æšæºãã¯ã¬ãªããé
åã¯ãå®å®çèçœè³ªâçµåã圢æããã
第ïŒèŠªåæ§è©Šè¬ã¯ã倩ç¶ã®ãã¯ã¬ãªãœãŒã åã³ç¬¬ïŒãšãããŒããå«ãæšæºã®éã䞊ã³ã«ã第ïŒãšãããŒããå«ãææããã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã«é¢ããæå®ã®ãã¯ã¬ãªããé
åã®éãšãããŒãã©ã€ãã©ãªç±æ¥ã®ã€ã³ãããéã®å€©ç¶ã®ãã¯ã¬ãªãœãŒã ã«é¢ããæå®ã®ãã¯ã¬ãªããé
åã®éãšãæ¯èŒããããšã«ãã決å®ããã第ïŒãšãããŒãã«å¯Ÿããçžå¯Ÿçã²ãã æ°ãææããããã«ããŒãã©ã€ãã©ãªã«æ·»å ãããã第ïŒãšãããŒãã«å¯Ÿããæšæºææå¹çã¯ãææãããæšæºã«é¢ããããŒã³ãŒãé
åã®éãšãããŒãã©ã€ãã©ãªç±æ¥ã®ã€ã³ãããéã®æšæºã«é¢ããæå®ã®ãã¯ã¬ãªããé
åã®éãšãæ¯èŒããããšã«ãã決å®ããããã²ãã éºäŒå座ã§ã®ã³ã¢ãã¹ãã³ã®ç¬¬ïŒãšãããŒãã®å¯åºŠã¯ãæšæºææå¹çã«å¯Ÿããçžå¯Ÿçã²ãã æ°ãæ¯èŒããããšã«ãã決å®ãããã
äžå®æœåœ¢æ
ã«ãããŠã¯ãæšæºææå¹çã®æž¬å®ã¯ãåæ§æãã¯ã¬ãªãœãŒã ã®ã€ã³ãããéã«å¯ŸããããŒã³ãŒãååã®ææéã®æ¯çãå«ããä»ã®å®æœåœ¢æ
ã«ãããŠã¯ãçžå¯Ÿçã²ãã æ°ã®æž¬å®ã¯ã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã®ãã¯ã¬ãªããé
åã®ã€ã³ãããéã«å¯Ÿãã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã®ãã¯ã¬ãªããé
åã®ææéã®æ¯çã®æ¯èŒãå«ãããããªãä»ã®å®æœåœ¢æ
ã«ãããŠã¯ã第ïŒèŠªåæ§è©Šè¬ç¬¬ïŒãšãããŒãã«å¯Ÿããæäœã§ããã
ããå®æœåœ¢æ
ã«ãããŠã¯ãè€æ°ã®æšæºãã©ã€ãã©ãªã«æ·»å ãããåæšæºã¯ãïŒïœïŒç¬¬ïŒãšãããŒããæããæšæºãã¹ãã³ãšãïŒïœïœïŒããŒã³ãŒãååã«çµåããæšæºãã¯ã¬ãªããé
åãå«ãæšæºååãšãå«ãåæ§æãã¯ã¬ãªãœãŒã ãå«ã¿ãããŒã³ãŒãååã¯ãã©ã€ãã©ãªã«æ·»å ãããæšæºã瀺ãæ¿åºŠãã©ã¡ãŒã¿ãã³ãŒãåããå°ãªããšãïŒã€ã®ç°ãªãæ¿åºŠãæããæšæºãã©ã€ãã©ãªã«æ·»å ããããè€æ°ã®æšæºã¯ãïŒïœïŒïŒã€ä»¥äžã®ãªãã¿ãŒã²ããã®ãšãããŒããšãïŒïœïœïŒãªãã¿ãŒã²ããã®ãšãããŒãã®åäžæ§åã³ãªãã¿ãŒã²ããã®ãšãããŒãã瀺ãæ¿åºŠãã©ã¡ãŒã¿ãã³ãŒãåããæšæºååããŒã³ãŒããšãå«ãåæ§æãã¯ã¬ãªãœãŒã ãå«ãæšæºãããã«æ·»å ããŠãããã
ãïœïŒ°ïŒ£ïŒ²ãïœïœïŒ°ïŒ£ïŒ²ã次äžä»£ã·ãŒã¯ãšã³ã·ã³ã°ããã€ããªãã€ãŒãŒã·ã§ã³ããªãŒãã©ãžãªã°ã©ãã£ãèå
ã©ããªã³ã°ãå
åŠå¯åºŠåã³ãåã³ãã€ã³ã¿ãŒã«ã¬ãŒã¿ãŒæ§èå
ãããŒãã®äœ¿çšãããªãäžçŸ€ããéžæãããæ¹æ³ã«ããããã¯ã¬ãªãœãŒã ã®ãã¯ã¬ãªããé
ååã³æšæºã®ãã¯ã¬ãªããé
åã®å°ãªããšãïŒã€ã®æ°ã枬å®ããŠããããã³ã¢ãã¹ãã³ã®ç¬¬ïŒãšãããŒãã¯ãã»ãªã³åã³ã¢ã©ãã³ã®ïŒ®âã¢ã»ãã«åïŒã»ãªã³ãã¹ã¬ãªãã³åã³ããã·ã³ã®ãªã³é
žåïŒãªãžã³ã®ïŒ®âã¯ãããã«åãâã¢ã»ãã«åïŒãªãžã³ã®ïŒ®ïŒâã¡ãã«åãïŒïŒïŒ®ïŒâãžã¡ãã«åãïŒïŒïŒ®ïŒïŒïŒ®ïŒâããªã¡ãã«åïŒã¢ã«ã®ãã³ã®ãªã¡ã¬ââã¡ãã«åã察称æ§ãžã¡ãã«åãé察称æ§ãžã¡ãã«åïŒã¢ã«ã®ãã³ã®ã·ãã«ãªã³åïŒãªãžã³ã®ãŠãããã³åïŒãªãžã³ã®ïŒ³ïŒµïŒïŒ¯åïŒã»ãªã³åã³ã¹ã¬ãªãã³ã®ïŒ¯âã¡ãã«åïŒäžŠã³ã«ãã¢ã«ã®ãã³ãã¢ã¹ãã©ã®ã³é
žåã³ã°ã«ã¿ãã³é
žã®ïŒ¡ïŒ€ïŒ°âãªããŒã¹åãããªãäžçŸ€ããéžæãããå°ãªããšãïŒã€ã®ç¿»èš³åŸã¢ããé
žä¿®é£Ÿãå«ãã§ãããã
ä»ã®å®æœåœ¢æ
ã¯ã现èã®ã¯ãããã³å
ã®ã²ãã éºäŒå座ã§ã³ã¢ãã¹ãã³ã®ç¬¬ïŒãšãããŒãã®å¯åºŠã枬å®ããæ¹æ³ãæäŸããããã®æ¹æ³ã¯ãã¯ãããã³ãã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã®ã©ã€ãã©ãªãæºåããå·¥çšãåããåèšã©ã€ãã©ãªã¯ãã³ã¢ãã¹ãã³åã³åºç¹ã®ã²ãã éºäŒå座ã瀺ããã¯ã¬ãªãœãŒã ãã¯ã¬ãªããé
åãããããå«ããã¯ã¬ãªãœãŒã ãæãããæšæºã¯ããŒãã©ã€ãã©ãªãäœæããããã«ã©ã€ãã©ãªã«è¿œå ãããåèšæšæºã¯ãïŒïœïŒç¬¬ïŒãšãããŒããæããæšæºãã¹ãã³åã¯æšæºãã¹ãã³ãã©ã°ã¡ã³ãåã³ïŒïœïœïŒããŒã³ãŒããæããæšæºååãå«ãåæ§æãã¯ã¬ãªãœãŒã ãå«ã¿ãåèšæšæºãã¹ãã³åã¯æšæºãã¹ãã³ãã©ã°ã¡ã³ãåã³æšæºååã¯ãå®å®çãªèçœè³ªâçµåã圢æããã
ã³ã¢ãã¹ãã³ã®éã¯ããŒãã©ã€ãã©ãªäžã®ã²ãã éºäŒå座ã§èšæž¬ãããããŒãã©ã€ãã©ã«ãããæšæºã®éã¯æž¬å®ãããã芪åæ§è©Šè¬ã¯ããŒãã©ã€ãã©ãªã«æ·»å ããããšãããŒããå«ãæææšæºã®éåã³ããŒãã©ã€ãã©ãªå
ã®ã²ãã éºäŒå座ã§ã®ã³ã¢ãã¹ãã³ã®éã«åºã¥ãã倩ç¶ã®ãã¯ã¬ãªãœãŒã åã³ãšãããŒããå«ãåæ§æãã¯ã¬ãªãœãŒã ã®éåã³ã²ãã éºäŒå座ã§æž¬å®ããã第ïŒãšãããŒãã«å¯Ÿããçžå¯Ÿçã²ãã æ°ãææãããææãããåæ§æãã¯ã¬ãªãœãŒã ã®éåã³ããŒãã©ã€ãã©ãªå
ã®æšæºã®éã«åºã¥ãããšãããŒãã«å¯Ÿããæšæºã®ææå¹çã枬å®ãããã³ã¢ãã¹ãã³ã«å¯Ÿãã第ïŒãšãããŒãæ°åã³æšæºææå¹çã«åºã¥ããã²ãã éºäŒå座ã§ã®ã³ã¢ãã¹ãã³ã®ç¬¬ïŒãšãããŒãã®çžå¯Ÿçã²ãã æ°ã枬å®ãããã
äžå®æœåœ¢æ
ã«ãããŠã¯ãããŒãã©ã€ãã©ãªå
ã®ã²ãã éºäŒå座ã§ã®ã³ã¢ãã¹ãã³ã®éã®æž¬å®ã¯ãããŒãã©ã€ãã©ãªã«ç¬¬ïŒèŠªåæ§è©Šè¬ãæ·»å ãã第ïŒãšãããŒããå«ããã¯ã¬ãªãœãŒã ã®éãåãåºãå·¥çšãšã第ïŒãšãããŒããå«ãåãåºããããã¯ã¬ãªãœãŒã ã®éã«ããããã¯ã¬ãªãœãŒã ã®ãã¯ã¬ãªããé
åã®éã枬å®ããå·¥çšãšãå«ã¿ã第ïŒãšãããŒãã¯ã³ã¢ãã¹ãã³äžã«ååšããäžå€ã®ãšãããŒãã§ãããä»ã®å®æœåœ¢æ
ã«ãããŠã¯ãããŒãã©ã€ãã©ãªäžã®æšæºã®éã®æž¬å®ã¯ãåæ§æããããã¯ã¬ãªãœãŒã ã®éãåãåºãå·¥çšãšã第ïŒãšãããŒããå«ãåãåºãããåæ§æãã¯ã¬ãªãœãŒã ã®éã«ãããæšæºååã®éã枬å®ããå·¥çšãšãåããåæ§æããããã¯ã¬ãªãœãŒã ã¯ç¬¬ïŒãšãããŒããå«ãããããªãä»ã®å®æœåœ¢æ
ã«ãããŠã¯ã第ïŒèŠªåæ§è©Šè¬ã¯ç¬¬ïŒãšãããŒãã«å¯Ÿããæäœã§ããã第ïŒèŠªåæ§è©Šè¬ã¯ç¬¬ïŒãšãããŒãã«å¯Ÿããæäœã§ããã
ä»ã®æ
æ§ã¯ãé
å ïœïŒïŒâïŒïŒïŒãå«ãé
åãããªãäžçŸ€ããéžæããããã¯ã¬ãªããé
åãæãããã¯ã¬ãªãœãŒã ãå«ãçµæãæäŸããããããªãä»ã®æ
æ§ã¯ãããã«èšèŒãããæ¹æ³ãå®æœããããããæäŸãããäžå®æœåœ¢æ
ã«ãããŠã¯ããããã¯ãè€æ°ã®ãšãããŒããšããŒã³ãŒããå«ãæšæºååãå«ãïŒã€ä»¥äžã®æšæºãå«ããä»ã®å®æœåœ¢æ
ã«ãããŠã¯ããããã¯ãè€æ°ã®ãšãããŒãã®ãã¡ã®å°ãªããšãïŒã€ãèªèããå°ãªããšãïŒã€ã®èŠªåæ§è©Šè¬ãå«ãã
çšèªãå
ç«æ²éïŒïŒ©ïŒ°ïŒæ¿çž®ãã¯ãã€ã³ãããè©Šæç±æ¥ã®å
éšæšæºããåãããå
ç«æ²éãããè©Šæç±æ¥ã®å
éšæšæºãæå³ããã
èšèŒãããŠããããã«ããšãããŒãå¯åºŠã枬å®ããæ¹æ³ã®äžå®æœåœ¢æ
ã«ãããŠã¯ãæšæºèªèååãåããäžçµã®åèšååæãã¯ã¬ãªãœãŒã ã¯å€©ç¶ãã¯ã¬ãªãœãŒã ã®ã³ã¬ã¯ã·ã§ã³å
ã«ããŒããããããã®äžçµã¯ãé¢é£ã®å°ãªããšãïŒã€ã®ãšãããŒããå«ã¿ãïŒã€ä»¥äžã®ãšãããŒããå
éšã«å«ãæšæºèªèååãæããååæãã¯ã¬ãªãœãŒã ãæ§æãããäŸãã°ãäžçµã®ååæãã¯ã¬ãªãœãŒã ã¯ã翻蚳åŸä¿®é£Ÿãããªãã¡ïŒšïŒïŒ«ïŒïœïœ
ïŒåã³ãã¹ãã³ã®ããªããããé
åã®ãããªä¿åããåã¯å€ç°ããããšãããŒããå«ãã§ããããæãã¯ãäžçµã®ååæãã¯ã¬ãªãœãŒã ã¯ãïŒïŒ«ïŒïœïœ
ïŒã®ãããªïŒã€ä»¥äžã®ç¿»èš³åŸä¿®é£Ÿãå«ã¿ãåã¯ç¬¬ïŒãšãããŒããæ¿å
¥ããŠããããä»ã®æ
æ§ã«ãããŠã¯ãäžçµã®æšæºã¯ãé¢é£ã®ãšãããŒããšã¯ç°ãªãåœéœæ§ãšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããâèçœè³ªè€åäœãåããå°ãªããšãïŒã€ã®ååæãåæ§æãããåã¯å€ç°äœãå«ãã奜é©ãªå®æœåœ¢æ
ã«ãããŠã¯ãäžçµã®ååæåã¯å€ç°äœã¯ãçéœæ§ãšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããå°ãªããšãïŒã€ã®ãã¯ã¬ãªãœãŒã ã䞊ã³ã«ãåœéœæ§ãšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããå°ãªããšãïŒã€ã®ãã¯ã¬ãªãœãŒã ãå«ããã¯ã¬ãªãœãŒã ãåããã
ïœ
âïœïŒ©ïŒ°ããŒã¿åæ
äžå®æœåœ¢æ ã«ãããŠã¯ãïŒ©ïŒ£ïœ âïœïŒ©ïŒ°ãå®æœããããã«ãïœïŒ©ïŒ°èªã¿åããæ¯èŒãããäžçµã®åèšå éšæšæºã¯ã倩ç¶ïŒ€ïŒ®ïŒ¡âèçœè³ªè€åäœã®ã³ã¬ã¯ã·ã§ã³å ã«ããŒããããã以äžã«ããããã®æšæºãã©ã®ããã«æšæºïŒ©ïŒ°å¹çã®ç®åºã«çšããããããåæ§ã«ãç 究ããããšãããŒããå€ç°èçœè³ªãã©ã°ã¡ã³ããèçœè³ªã€ã³ãã©ããŒåã¯èçœè³ªç¿»èš³åŸä¿®é£Ÿãã©ããã«äŸåããŠãèçœè³ªåã¯ãšãããŒãå¯åºŠïŒïŒ°ïŒ€ïŒãèçœè³ªå€ç°äœå¯åºŠïŒïŒ°ïŒ¶ïŒ€ïŒåã¯èçœè³ªä¿®é£Ÿå¯åºŠïŒïŒ°ïŒïŒ€ïŒãäœãšåŒã°ãããç®åºããããã«çšããããããšãæã ã¯èšèŒããã倩ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæãããã¯ã¬ãªãœãŒã ãå«ãååæåã¯å€ç°äœã«åºã¥ãæšæºã¯ããã¹ãã³ä¿®é£Ÿå¯åºŠïŒïŒšïŒïŒ€ïŒåã¯ãã¹ãã³å€ç°äœå¯åºŠïŒïŒšïŒ¶ïŒ€ïŒã®çµ¶å¯Ÿçå®éãè¡ãããšã«ãããã¯ãããã³å ç«æ²éæ³ãæ¹è¯ããã
äžå®æœåœ¢æ ã«ãããŠã¯ãïŒ©ïŒ£ïœ âïœïŒ©ïŒ°ãå®æœããããã«ãïœïŒ©ïŒ°èªã¿åããæ¯èŒãããäžçµã®åèšå éšæšæºã¯ã倩ç¶ïŒ€ïŒ®ïŒ¡âèçœè³ªè€åäœã®ã³ã¬ã¯ã·ã§ã³å ã«ããŒããããã以äžã«ããããã®æšæºãã©ã®ããã«æšæºïŒ©ïŒ°å¹çã®ç®åºã«çšããããããåæ§ã«ãç 究ããããšãããŒããå€ç°èçœè³ªãã©ã°ã¡ã³ããèçœè³ªã€ã³ãã©ããŒåã¯èçœè³ªç¿»èš³åŸä¿®é£Ÿãã©ããã«äŸåããŠãèçœè³ªåã¯ãšãããŒãå¯åºŠïŒïŒ°ïŒ€ïŒãèçœè³ªå€ç°äœå¯åºŠïŒïŒ°ïŒ¶ïŒ€ïŒåã¯èçœè³ªä¿®é£Ÿå¯åºŠïŒïŒ°ïŒïŒ€ïŒãäœãšåŒã°ãããç®åºããããã«çšããããããšãæã ã¯èšèŒããã倩ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæãããã¯ã¬ãªãœãŒã ãå«ãååæåã¯å€ç°äœã«åºã¥ãæšæºã¯ããã¹ãã³ä¿®é£Ÿå¯åºŠïŒïŒšïŒïŒ€ïŒåã¯ãã¹ãã³å€ç°äœå¯åºŠïŒïŒšïŒ¶ïŒ€ïŒã®çµ¶å¯Ÿçå®éãè¡ãããšã«ãããã¯ãããã³å ç«æ²éæ³ãæ¹è¯ããã
ãå¹çãã¯ãïŒã€ä»¥äžã®ãã«ããŠã³éã®ãšãããŒãã®çžå¯Ÿçåãåºããæå³ãããæšæºã«å¯Ÿããå¹çã®ç¥èŠã¯ãïŒã€ä»¥äžã®ãã«ããŠã³éã®åãåºãã®å·®ãä¿®æ£ããããšã«ãã絶察çå®éã®å®æœãå¯èœãšãããäžå®æœåœ¢æ
ã«ãããŠã¯ãåèšïŒ©ïŒ°å¹çã¯ã倩ç¶ãšãããŒããšåã芪åæ§ãç¹ç°æ§åã³çµå掻æ§ãæããæ°ãè€åæ··åç©äžã§å®¹æã«æž¬å®ãããäžçµã®åèšæšæºãçšããããšã«ãã枬å®ãããããããã®ååææšæºã¯ãå°ãªã倩ç¶ïŒ€ïŒ®ïŒ¡âèçœè³ªè€åäœã芪åæ§ææã®å¯Ÿè±¡ãšãªãè©Šæäžã«ããŒããããããã®ã¹ãããã®åŸããšãããŒãæ°åã³äžè¬çãªèçœè³ªå¯åºŠã®åèšæž¬å®ã¯ãåèšæ°æž¬å®ã®æ¹æ³ã®ïŒã€ãæããååææšæºåã³å°ãªã倩ç¶ïŒ€ïŒ®ïŒ¡âèçœè³ªè€åäœçŸ€ã«å¯ŸããŠå®æœããããäžå®æœåœ¢æ
ã«ãããŠã¯ãäžçµã®æšæºã¯ãç°ãªãæ¿åºŠã§æ·»å ãããæšæºãå«ããããã§ãæ·»å ãããæ¿åºŠã¯ãããŒã³ãŒãã«ããç¬ç¹ã«åå®ãããã
çŽæ¥å
éšæšæºæ ¡æ£ã¯ãæ¬æ¥ã®è©Šæã«ããã粟æ»ããããšãããŒãã®çµ¶å¯Ÿçã¢ã«æ°ãå€æ¿æ³ã«ããæšå®ããããã«ãã€ã³ãããã«ãããåå
éšæšæºã©ããŒã¡ã³ããŒã®æ£ç¢ºãªã¢ã«æ¿åºŠã枬å®ããïœïŒ©ïŒ°å·¥çšãéããŠæ·»å ãããããŒã³ãŒãåãã¯ã¬ãªãœãŒã æšæºã®ã¿ã°èšæ°ã枬å®ããããã®çš®é¡ã®æ ¡æ£ã¯ãå°çèãã¯ã¬ã¢ãŒãŒæ¶åãæœããã现èæ žèšæ°ã®æ£ç¢ºæ§ãåã³ããã®è¯å¥œãªå®éæ°ãã培åºçã«ãã©ã°ã¡ã³ãåãããã¯ãããã³åé¢ã®éäžã§çãããã€ã¢ã¹ã®ãããããæ倱ã«ããéå®ããããé«ãæé©åãããæ¶ååã³åé¢æ¡ä»¶äžã§æ¶åããã现èæ žç±æ¥ã®ç·æ žé
žã®ïŒïŒïŒ
ãããããåãåºãããããã€ã¢ã¹ã®ãããããã²ãã åãåºãã«èµ·å ããåæ誀差ãããïŒäŸãã°ãéç¹èš±æç®ïŒåç
§ãïŒã
è©Šè¬åã³ããã
æ¬çºæã®ä»ã®æ æ§ã¯ãããã«èšèŒãããæ¹æ³ã®ïŒã€ãå®æœããè©Šè¬ãå«ãè©Šè¬åã³ããããæäŸãããè©Šè¬ã¯é©åãªããã±ãŒãžåã¯å®¹åšã«å«ãŸããããããã¯ãäŸãã°ãã«ããŠã³ã¢ãã»ã€åã¯ã¯ãããã³å ç«æ²éã¢ãã»ã€ã«ãããŠãçéœæ§åã³åœéœæ§ãšãããŒãã®çµ¶å¯Ÿçå®éã®ããã®ããã«èšèŒãããæšæºãå«ãïŒã€ä»¥äžã®è©Šè¬ãå«ãããããã¯ãããã«èšèŒãããå°ãªããšãïŒã€ã®èŠªåæ§è©Šè¬ãäŸãã°æäœãå«ããæšæºã¯ãçéœæ§ãšãããŒãã«å¯ŸããŠå€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããããããã¯ãåœéœæ§ãšãããŒãã«å¯ŸãããšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããå°ãªããšãïŒã€ã®æšæºãå«ãã
æ¬çºæã®ä»ã®æ æ§ã¯ãããã«èšèŒãããæ¹æ³ã®ïŒã€ãå®æœããè©Šè¬ãå«ãè©Šè¬åã³ããããæäŸãããè©Šè¬ã¯é©åãªããã±ãŒãžåã¯å®¹åšã«å«ãŸããããããã¯ãäŸãã°ãã«ããŠã³ã¢ãã»ã€åã¯ã¯ãããã³å ç«æ²éã¢ãã»ã€ã«ãããŠãçéœæ§åã³åœéœæ§ãšãããŒãã®çµ¶å¯Ÿçå®éã®ããã®ããã«èšèŒãããæšæºãå«ãïŒã€ä»¥äžã®è©Šè¬ãå«ãããããã¯ãããã«èšèŒãããå°ãªããšãïŒã€ã®èŠªåæ§è©Šè¬ãäŸãã°æäœãå«ããæšæºã¯ãçéœæ§ãšãããŒãã«å¯ŸããŠå€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããããããã¯ãåœéœæ§ãšãããŒãã«å¯ŸãããšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããå°ãªããšãïŒã€ã®æšæºãå«ãã
ä»ã®å¥œé©ãªå®æœåœ¢æ
ã«ãããŠã¯ãåèšæšæºã¯ã倩ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæãããã¹ãã³ããã¹ãã³ã¢ã€ãœãã©ãŒã åã¯ãã¹ãã³ç¿»èš³åŸä¿®é£ŸãæããŠäœæãããååæãã¯ã¬ãªãœãŒã 䞊ã³ã«ããŒã³ãŒãååãæããâèçœè³ªè€åäœãå«ããæ§ã
ãªå®æœåœ¢æ
ã«ãããŠã¯ãè¡šïŒãïŒã«ãããŠå®çŸ©ããããã®ãå«ãåœæ¥è
ã«å
¬ç¥ãªã³ã¢ãã¹ãã³é
ååã¯ç¿»èš³åŸä¿®é£Ÿã®ããããã®å€ç°äœã¯ããšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãä¿æãããä»®å®ã®ããšãã¹ãã³ãªã¯ã¿ããŒãå«ããã¹ãã³äžã«åãä»ããããã奜é©ãªå®æœåœ¢æ
ã«ãããŠã¯ãäžçµã®æšæºã¯ãçéœæ§ãšãããŒãã«å¯ŸãããšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããè€åäœã®å°ãªããšãïŒã€ã®æšæºãåã³ã倩ç¶ã®å°ãªãâèçœè³ªè€åäœã«ãããŠååšããå¯èœãªãªãã¿ãŒã²ãããšãããŒãïŒåœéœæ§ãšãããŒãïŒã®ç¯å²ãã«ããŒãããšãããŒãã®å€©ç¶æ§èŠªåæ§ãç¹ç°æ§åã³çµå掻æ§ãæããè€åäœã®è€æ°ã®æšæºããæ§æãããã
ä»ã®å®æœåœ¢æ
ã«ãããŠã¯ããããã¯ãããã±ãŒãžå容åšäžã«ïŒã€ä»¥äžã®æŽæµãããã¡ïŒäŸãã°ãªã³é
žç·©è¡é£å¡©æ°ŽïŒåã³ïŒåã¯ä»ã®ãããã¡ãå«ãããããªãä»ã®å®æœåœ¢æ
ã«ãããŠã¯ããããã¯ã第ïŒæäœåã¯èçœè³ªïŒ¡ã«çµåããããäŸãã°åžžç£æ§ç²åãå«ãææè©Šè¬ãäŸãã°åºçžææè©Šè¬ã®åé¢ã®ããã«å¿
èŠãªè©Šè¬ãå«ãããããã¯ãæææšæºåã¯è©Šæã®éã®æž¬å®ã«å¿
èŠãªè©Šè¬ãå«ãã
Claims (22)
- 现èã®ã¯ãããã³å ã®ã²ãã éºäŒå座ã§ã³ã¢ãã¹ãã³ã®ç¬¬ïŒãšãããŒãã®å¯åºŠã枬å®ããæ¹æ³ã§ãã£ãŠã
åèšã¯ãããã³ãã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã®ã©ã€ãã©ãªãæºåããå·¥çšãšã
ããŒãã©ã€ãã©ãªãäœæããããã«åèšã©ã€ãã©ãªã«æšæºãè¿œå ããå·¥çšãšã
åèšç¬¬ïŒãšãããŒããå«ã倩ç¶ã®ãã¯ã¬ãªãœãŒã åã³æšæºã®éãææããããã«åèšããŒãã©ã€ãã©ãªã«ç¬¬ïŒèŠªåæ§è©Šè¬ãè¿œå ããå·¥çšãšã
åèšç¬¬ïŒãšãããŒããå«ãææããã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã«é¢ããææã®ãã¯ã¬ãªããé åã®éãšãåèšããŒãã©ã€ãã©ãªããã®ã€ã³ãããéã«ããã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã«é¢ããææã®ãã¯ã¬ãªããé åã®éãšãæ¯èŒããããšã«ãã£ãŠåèšç¬¬ïŒãšãããŒãã«å¯Ÿããçžå¯Ÿçã²ãã æ°ã枬å®ããå·¥çšãšã
ææãããæšæºååã«é¢ããããŒã³ãŒãé åã®éãšãåèšããŒãã©ã€ãã©ãªããã®ã€ã³ãããéã«ãããåèšæšæºååã«é¢ããææã®ãã¯ã¬ãªããé åã®éãšãæ¯èŒããããšã«ãã£ãŠåèšç¬¬ïŒãšãããŒãã«å¯Ÿããæšæºææå¹çã枬å®ããå·¥çšãšã
åèšæšæºææå¹çã«å¯Ÿããåèšçžå¯Ÿçã²ãã æ°ãæ¯èŒããããšã«ãã£ãŠåèšã²ãã éºäŒå座ã§åèšã³ã¢ãã¹ãã³ã®åèšç¬¬ïŒãšãããŒãã®å¯åºŠã枬å®ããå·¥çšãšãåãã
åèšã©ã€ãã©ãªã¯ãåèšç¬¬ïŒãšãããŒããæããåèšã³ã¢ãã¹ãã³åã³åèšã²ãã éºäŒå座ã瀺ããã¯ã¬ãªãœãŒã ãã¯ã¬ãªããé åãå«ããã¯ã¬ãªãœãŒã ãæãã
åèšæšæºã¯ãïŒïœïŒåèšç¬¬ïŒãšãããŒããæããæšæºãã¹ãã³åã¯æšæºãã¹ãã³ãã©ã°ã¡ã³ãåã³ïŒïœïœïŒããŒã³ãŒãååã«ãªã³ã¯ããæšæºãã¯ã¬ãªããé åãæããæšæºååãå«ãåæ§æãã¯ã¬ãªãœãŒã ãå«ã¿ã
åèšæšæºãã¹ãã³åã¯æšæºãã¹ãã³ãã©ã°ã¡ã³ãåã³åèšæšæºãã¯ã¬ãªããé åã¯ãå®å®çãªèçœè³ªâçµåã圢æããããšãç¹åŸŽãšããæ¹æ³ã - åèšæšæºææå¹çã®æž¬å®ã¯ãåèšåæ§æãã¯ã¬ãªãœãŒã ã®ã€ã³ãããéã«å¯ŸããåèšããŒã³ãŒãååã®ææéã®æ¯çã®æ¯èŒãå«ãããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- åèšçžå¯Ÿçã²ãã æ°ã®æž¬å®ã¯ã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã®ãã¯ã¬ãªããé åã®ã€ã³ãããéã«å¯Ÿãã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã®ãã¯ã¬ãªããé åã®ææéã®æ¯çã®æ¯èŒãå«ãããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- åèšç¬¬ïŒèŠªåæ§è©Šè¬ã¯åèšç¬¬ïŒãšãããŒãã«å¯Ÿããæäœã§ããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- è€æ°ã®æšæºã¯åèšã©ã€ãã©ãªã«è¿œå ããã
åèšæšæºã®ããããã¯ãïŒïœïŒåèšç¬¬ïŒãšãããŒããæããåèšæšæºãã¹ãã³ãšãïŒïœïœïŒåèšããŒã³ãŒãååã«ãªã³ã¯ããåèšæšæºãã¯ã¬ãªããé åãæããåèšæšæºååãšãåããåæ§æãã¯ã¬ãªãœãŒã ãå«ã¿ã
åèšããŒã³ãŒãååã¯ãåèšã©ã€ãã©ãªã«è¿œå ãããåèšæšæºã®æ¿åºŠã瀺ãæ¿åºŠãã©ã¡ãŒã¿ãã³ãŒãåãã
å°ãªããšãïŒã€ã®ç°ãªãæ¿åºŠãæããæšæºååãåèšã©ã€ãã©ãªã«è¿œå ãããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã - åèšè€æ°ã®æšæºã¯ãïŒïœïŒïŒã€ä»¥äžã®ãªãã¿ãŒã²ããã®ãšãããŒããšãïŒïœïœïŒãªãã¿ãŒã²ããã®ãšãããŒãã®åäžæ§åã³åèšãªãã¿ãŒã²ããã®ãšãããŒãã瀺ãæ¿åºŠãã©ã¡ãŒã¿ãã³ãŒãåããæšæºååããŒã³ãŒããšãå«ãåæ§æãã¯ã¬ãªãœãŒã ãæããæšæºãããã«å«ãããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- ãªãã¿ãŒã²ããã®ãšãããŒãã«å¯ŸããïŒã€ä»¥äžã®ææå¹çã«åºã¥ããŠãåèšç¬¬ïŒèŠªåæ§è©Šè¬ã«å¯Ÿãããªãã¿ãŒã²ããææã®ç¹ç°æ§ã枬å®ããå·¥çšãšã
åèšãªãã¿ãŒã²ããææã®ç¹ç°æ§ã«åºã¥ããŠãåèšã²ãã éºäŒå座ã®åèšã³ã¢ãã¹ãã³ã®åèšç¬¬ïŒãšãããŒãã®å¯åºŠãä¿®æ£ããå·¥çšãšãããã«åããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã - åèšç¬¬ïŒãšãããŒãã¯ç¿»èš³åŸä¿®é£Ÿåã¯èçœè³ªã®ã¢ã€ãœãã©ãŒã ã§ããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- åèšããŒã³ãŒãé åã¯åèšçŽ°èã®ã²ãã å ã«ååšããªãé åã§ããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- åèšãã¯ã¬ãªãœãŒã ãã¯ã¬ãªããé ååã³åèšæšæºãã¯ã¬ãªããé åã®å°ãªããšãïŒã€ã®æ°ã¯ããïœïŒ°ïŒ£ïŒ²ãïœïœïŒ°ïŒ£ïŒ²ã次äžä»£ã·ãŒã¯ãšã³ã·ã³ã°ããã€ããªãã€ãŒãŒã·ã§ã³ããªãŒãã©ãžãªã°ã©ãã£ãèå ã©ããªã³ã°ãå åŠå¯åºŠåã³ãåã³ãã€ã³ã¿ãŒã«ã¬ãŒã¿ãŒæ§èå ãããŒãã®äœ¿çšãããªãäžçŸ€ããéžæãããæ¹æ³ã«ãã枬å®ãããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- åèšã³ã¢ãã¹ãã³ã®åèšç¬¬ïŒãšãããŒãã¯ãã»ãªã³åã³ã¢ã©ãã³ã®ïŒ®âã¢ã»ãã«åïŒã»ãªã³ãã¹ã¬ãªãã³åã³ããã·ã³ã®ãªã³é žåïŒãªãžã³ã®ïŒ®âã¯ãããã«åãâã¢ã»ãã«åïŒãªãžã³ã®ïŒ®ïŒâã¡ãã«åãïŒïŒïŒ®ïŒâãžã¡ãã«åãïŒïŒïŒ®ïŒïŒïŒ®ïŒâããªã¡ãã«åïŒã¢ã«ã®ãã³ã®ãªã¡ã¬ââã¡ãã«åã察称æ§ãžã¡ãã«åãé察称æ§ãžã¡ãã«åïŒã¢ã«ã®ãã³ã®ã·ãã«ãªã³åïŒãªãžã³ã®ãŠãããã³åïŒãªãžã³ã®ïŒ³ïŒµïŒïŒ¯åïŒã»ãªã³åã³ã¹ã¬ãªãã³ã®ïŒ¯âã¡ãã«åïŒäžŠã³ã«ãã¢ã«ã®ãã³ãã¢ã¹ãã©ã®ã³é žåã³ã°ã«ã¿ãã³é žã®ïŒ¡ïŒ€ïŒ°âãªããŒã¹åãããªãäžçŸ€ããéžæãããå°ãªããšãïŒã€ã®ç¿»èš³åŸã¢ããé žä¿®é£Ÿãå«ãããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- åèšæšæºååã¯ãäºæ¬éããªãã¯ã¬ãªããã§ããããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- åèšäºæ¬éããªãã¯ã¬ãªããã¯ãé å ïœïŒïŒâïŒïŒïŒãããªãäžçŸ€ããéžæããããã¯ã¬ãªããé åãæããããšãç¹åŸŽãšããè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã
- åèšããŒã³ãŒãååã¯ããã¯ã¬ãªããããŒã³ãŒãé åååãããã¯ãæ žé žé ååã³ïŒ€ïŒ®ïŒ¡é åãããªãäžçŸ€ããéžæãããååãå«ãããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ã
- åèšçŽ°èã¯æ£è ç±æ¥ã®çŽ°èã§ããã
ææã®éºäŒå座ã®åèšç¬¬ïŒãšãããŒãã®éã¯ãè 现èçãç¥çµè è «ãç¥çµè èè «ãæªæ§æç¶çŽ°èè «ã骚èœçŽ°èè «ãèºçãå°çŽ°èæ§èºçãåå®®é žçãå€§è žçãçŽè žçãèçŽ¢è «ãåœé çãã«ããžèè «ããªã³ã管èè «ããªã³ã管å ç®çŽ°èèè «ãçµè žçŽè žçãåå®®å èçãåµå·£çãä¹³çãèµèçãåç«è ºçãè 现èçãè现èçãè管çã絚æ¯çã粟äžç®è «ãçŸäžžè «çããŠã£ã«ã ã¹è «çããŠãŒã€ã³ã°çãèè±çãè¡ç®¡èè «ãå ç®èè «ãè ºçãæ±è ºçãç®èè ºèè «ãä¹³é èè «ãä¹³é è ºèè «ãå¢èè ºèè «ãæ°ç®¡æ¯åæ§èºçãé«æ§çããã¹ã现èè «ãäžç®è «ãæ»èè «ãé»è²è «ãå¹³æ»çèè «ã暪çŽçèè «ãç¥çµèœçŽ°èè «ã網èèœçŽ°èè «ãä¹çªèµ·ç¥çµè è «ãèŽç¥çµè «çãè¡ç®¡èœçŽ°èè «ãé«èè «ãæŸæäœè «ãè³å®€äžè¡£çŽ°èè «ãé èåœé è «ãäžç®çãèæ§çè «çŽ°èãæå¹³äžç®çãåºåºçŽ°èçãç·ç¶èè «ãç²æ¶²è «ãç²æ¶²èè «ãç¥çµè è «ãèèªèè «ïŒããªã³ãã¯ã¿ãŒãããªããªã¹ããªã¢ã»ã¢ããµã€ãã²ãã¹ãã·ã²ã©ã»ãã¬ãã¯ã¹ããªãã¢ããã©ãºãã»ãã¡ãŽãµã€ããã£ã«ã ãã¯ã©ãããã£ã©ããšãã¹ã¿ã€ã³âããŒãŠã€ã«ã¹ããã«ãã¹ãããã«ãã«ãäœè¡åžè«ã«èµ·å ããææçïŒè¥æºãç³å°¿ç ãå¿èç ïŒèªéçãè匱æè²äœçå矀ãâçå矀ãã¢ã³ãžã§ã«ãã³çå矀ããã©ãâãŠã£ãªçå矀ãããã¯ãŠã£ãºâãŽã£ãŒããã³çå矀ãã¬ããçå矀ãã«ãã³ã·ã¥ã¿ã€ã³âãã€ãçå矀ãã³ãã£ã³âããŒãªãŒçå矀ãå ç«äžå šâã»ã³ããã¡ã¢äžå®å®æ§âé¡è²ç°åžžçå矀ãαâãµã©ã»ãã¢ãçœè¡ç ããã³ãã³ãã³ç ã粟ç¥åè£ç ãå極æ§é害ãèåãçŽåãã¢ã«ããã€ããŒç ãããŒãã³ãœã³ç ãã³ã«ããªã¢ã»ãã»ã©ã³ã²çå矀ãæèäŒã¡ãŒãã£ããçå矀ãã·ã§ãŒã°ã¬ã³çå矀ãå°åžžæ§çœæãé²è¡æ§å šèº«æ§ç¡¬åçã也ç¬ãåçºæ§èæ±æ§è硬å€ãã¯ããŒã³ç åã³æœ°çæ§å€§è žçãæ©æ¬ç²ç¶è ºçãã°ã¬ãŒãã¹ç ãççæ§è žçŸæ£ãã¢ãããŒã æ§åè硬åçãåã³ãå¿è¥å€§ãããªãäžçŸ€ããéžæãããç æ°åã¯ç¶æ ã瀺ãããšãç¹åŸŽãšããè«æ±é ïŒã®æ¹æ³ã - 现èã®ã¯ãããã³å ã®ã²ãã éºäŒå座ã§ã³ã¢ãã¹ãã³ã®ç¬¬ïŒãšãããŒãã®å¯åºŠã枬å®ããæ¹æ³ã§ãã£ãŠã
åèšã¯ãããã³ãã倩ç¶ã®ãã¯ã¬ãªãœãŒã ã®ã©ã€ãã©ãªãæºåããå·¥çšãšã
ããŒãã©ã€ãã©ãªãäœæããããã«åèšã©ã€ãã©ãªã«æšæºãè¿œå ããå·¥çšãšã
åèšããŒãã©ã€ãã©ãªå ã®åèšã²ãã éºäŒå座ã§åèšã³ã¢ãã¹ãã³ã®éã枬å®ããå·¥çšãšã
åèšããŒãã©ã€ãã©ãªå ã®æšæºã®éã枬å®ããå·¥çšãšã
åèšãšãããŒããå«ã倩ç¶ã®ãã¯ã¬ãªãœãŒã åã³åæ§æãã¯ã¬ãªãœãŒã ã®éãææããããã«åèšããŒãã©ã€ãã©ãªã«èŠªåæ§è©Šè¬ãè¿œå ããå·¥çšãšã
åèšãšãããŒããå«ãåèšæææšæºã®éåã³åèšããŒãã©ã€ãã©ãªå ã®åèšã²ãã éºäŒå座ã§ã®åèšã³ã¢ãã¹ãã³ã®éã«åºã¥ããŠãã²ãã éºäŒå座ã§åèšç¬¬ïŒãšãããŒãã«å¯Ÿããçžå¯Ÿçã²ãã æ°ã枬å®ããå·¥çšãšã
ææåæ§æãã¯ã¬ãªãœãŒã ã®éåã³åèšããŒãã©ã€ãã©ãªå ã®æšæºã®éã«åºã¥ããŠãåèšãšãããŒãã«å¯Ÿããæšæºææå¹çã枬å®ããå·¥çšãšã
åèšã³ã¢ãã¹ãã³ã«å¯Ÿããåèšç¬¬ïŒãšãããŒãæ°åã³åèšæšæºææå¹çã«åºã¥ããŠãåèšã²ãã éºäŒå座ã§åèšã³ã¢ãã¹ãã³ã®åèšç¬¬ïŒãšãããŒãã®åèšçžå¯Ÿçã²ãã æ°ã枬å®ããå·¥çšãšãåãã
åèšã©ã€ãã©ãªã¯ãåèšã³ã¢ãã¹ãã³åã³åºç¹ã®ã²ãã éºäŒå座ã瀺ããã¯ã¬ãªãœãŒã ãã¯ã¬ãªããé åãããããå«ããã¯ã¬ãªãœãŒã ãæãã
åèšæšæºã¯ãïŒïœïŒåèšç¬¬ïŒãšãããŒããæããæšæºãã¹ãã³åã¯æšæºãã¹ãã³ãã©ã°ã¡ã³ãåã³ïŒïœïœïŒããŒã³ãŒããæããæšæºååãå«ãåæ§æãã¯ã¬ãªãœãŒã ãå«ã¿ã
åèšæšæºãã¹ãã³åã¯æšæºãã¹ãã³ãã©ã°ã¡ã³ãåã³åèšæšæºååã¯ãå®å®çãªèçœè³ªâçµåã圢æããããšãç¹åŸŽãšããæ¹æ³ã - åèšããŒãã©ã€ãã©ãªäžã®ã²ãã éºäŒå座ã§åèšã³ã¢ãã¹ãã³ã®éãèšæž¬ããå·¥çšã¯ã
åèšããŒãã©ã€ãã©ãªã«ç¬¬ïŒèŠªåæ§è©Šè¬ãæ·»å ãã第ïŒãšãããŒããå«ããã¯ã¬ãªãœãŒã ã®éãåãåºãå·¥çšãšã
åèšç¬¬ïŒãšãããŒããå«ãåãåºããããã¯ã¬ãªãœãŒã ã®éã«ããããã¯ã¬ãªãœãŒã ã®ãã¯ã¬ãªããé åã®éã枬å®ããå·¥çšãšãåãã
åèšç¬¬ïŒãšãããŒãã¯ãåèšã³ã¢ãã¹ãã³äžã«ååšããäžå€ã®ãšãããŒãã§ããããšãç¹åŸŽãšããè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã - åèšããŒãã©ã€ãã©ãªäžã®æšæºã®éã®æž¬å®ã¯ã
åæ§æããããã¯ã¬ãªãœãŒã ã®éãåãåºãå·¥çšãšã
åèšç¬¬ïŒãšãããŒããå«ãåèšåãåºãããåæ§æãã¯ã¬ãªãœãŒã ã®éã«ãããåèšæšæºååã®éã枬å®ããå·¥çšãšãåãã
åèšåæ§æããããã¯ã¬ãªãœãŒã ã¯åèšç¬¬ïŒãšãããŒããå«ãããšãç¹åŸŽãšããè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã - åèšç¬¬ïŒèŠªåæ§è©Šè¬ã¯åèšç¬¬ïŒãšãããŒãã«å¯Ÿããæäœã§ãããåèšç¬¬ïŒèŠªåæ§è©Šè¬ã¯åèšç¬¬ïŒãšãããŒãã«å¯Ÿããæäœã§ããããšãç¹åŸŽãšããè«æ±é ïŒïŒã«èšèŒã®æ¹æ³ã
- é å ïœïŒïŒâïŒïŒïŒãå«ãé åãããªãäžçŸ€ããéžæããããã¯ã¬ãªããé åãæãããã¯ã¬ãªãœãŒã ãå«ãããšãç¹åŸŽãšããçµæç©ã
- è€æ°ã®ãšãããŒããå«ãïŒã€ä»¥äžã®æšæºåã³ããŒã³ãŒããå«ãæšæºååãå«ãããšãç¹åŸŽãšããè«æ±é ïŒã«èšèŒã®æ¹æ³ãå®æœãããããã
- åèšãããã¯ãè€æ°ã®ãšãããŒãã®ãã¡ã®å°ãªããšãïŒã€ãèªèããå°ãªããšãïŒã€ã®èŠªåæ§è©Šè¬ãå«ãããšãç¹åŸŽãšããè«æ±é ïŒïŒã«èšèŒã®ãããã
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461935129P | 2014-02-03 | 2014-02-03 | |
US61/935,129 | 2014-02-03 | ||
PCT/US2015/014296 WO2015117145A1 (en) | 2014-02-03 | 2015-02-03 | Compositions and methods for quantitative assesment of dna-protein complex density |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019122877A Division JP2019176878A (ja) | 2014-02-03 | 2019-07-01 | ïœïœâèçœè³ªè€åäœã®çµæç© |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017506073A JP2017506073A (ja) | 2017-03-02 |
JP2017506073A5 true JP2017506073A5 (ja) | 2019-08-08 |
JP6985010B2 JP6985010B2 (ja) | 2021-12-22 |
Family
ID=53757840
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016549801A Active JP6985010B2 (ja) | 2014-02-03 | 2015-02-03 | ïœïœâèçœè³ªè€åäœã®çµæåã³ãã®å¯åºŠã®å®éè©äŸ¡æ¹æ³ |
JP2019122877A Pending JP2019176878A (ja) | 2014-02-03 | 2019-07-01 | ïœïœâèçœè³ªè€åäœã®çµæç© |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019122877A Pending JP2019176878A (ja) | 2014-02-03 | 2019-07-01 | ïœïœâèçœè³ªè€åäœã®çµæç© |
Country Status (6)
Country | Link |
---|---|
US (2) | US10732185B2 (ja) |
EP (1) | EP3102721B1 (ja) |
JP (2) | JP6985010B2 (ja) |
CN (1) | CN107002289B (ja) |
ES (1) | ES2808651T3 (ja) |
WO (1) | WO2015117145A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3529400B1 (en) * | 2016-10-24 | 2021-02-17 | Geneinfosec, Inc. | Concealing information present within nucleic acids |
US20200332370A1 (en) * | 2018-01-10 | 2020-10-22 | EpiCypher, Inc | Methods for Quantification of Nucleosome Modifications and Mutations at Genomic Loci and Clinical Applications Thereof |
AU2019228625A1 (en) * | 2018-03-01 | 2020-09-03 | Epicypher, Inc. | Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes |
FR3082103B1 (fr) | 2018-06-08 | 2020-08-28 | Decathlon Sa | Procede de fabrication d'une chaussure, et chaussure susceptible d'etre obtenue par ledit procede |
WO2019237244A1 (en) * | 2018-06-12 | 2019-12-19 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Use of ubiquitylation of histone 2a protein |
CN108680757B (zh) * | 2018-06-29 | 2021-02-09 | äžæµ·äº€éå€§åŠ | äžç§æ£æµèçœèŽšådnaçžäºäœçšçè¯åçäžæ¹æ³ååºçš |
WO2020041148A1 (en) * | 2018-08-20 | 2020-02-27 | 10X Genomics, Inc. | Methods and systems for detection of protein-dna interactions using proximity ligation |
CN111009286B (zh) * | 2018-10-08 | 2023-04-28 | æ·±å³å倧å æºå»è¯ç§ææéå ¬åž | å¯¹å®¿äž»æ ·æ¬è¿è¡åŸ®çç©åæçæ¹æ³åè£ çœ® |
WO2020097294A1 (en) * | 2018-11-08 | 2020-05-14 | University Of Miami | Materials and methods for chromatin immunoprecipitation |
EP3899042A4 (en) * | 2018-12-21 | 2022-10-12 | Epicypher, Inc. | DNA BARCODED NUCLEOSOMES FOR CHROMATINA IMAGE ASSAYS |
JP2022520616A (ja) * | 2019-02-15 | 2022-03-31 | ãšããµã€ãã¡ãŒïŒã€ã³ã³ãŒãã¬ã€ããã | ã¯ãããã³äŒåã¿ã³ãã¯è³ªã®å®éçãããã³ã° |
US20220259585A1 (en) * | 2019-03-04 | 2022-08-18 | The Texas A&M University System | Methods of making and utilizing amber-obligated phage display libraries |
CN110988362B (zh) * | 2019-12-20 | 2023-11-14 | è¿å çç©è¡ä»œæéå ¬åž | æç»èçœæäœæµå®è¯åãè¯åçåå ¶äœ¿çšæ¹æ³ |
CA3195344A1 (en) * | 2020-11-02 | 2022-05-05 | Matthew R. MARUNDE | Improved assays to quantify chromatin targets using antibody-targeted enzyme digestion |
CN112375138B (zh) * | 2020-11-13 | 2022-12-13 | äžå æ±åçç©ææ¯è¡ä»œæéå ¬åž | äžç§éç»èœœèèçœeååºçš |
GB202108185D0 (en) * | 2021-06-08 | 2021-07-21 | Belgian Volition Sprl | Standardisation of nucleosome assays using biologically derived calibrants |
WO2024081782A1 (en) * | 2022-10-12 | 2024-04-18 | Epicypher, Inc. | High efficiency antibodies for chromatin targets |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012047726A1 (en) * | 2010-09-29 | 2012-04-12 | The Broad Institute, Inc. | Methods for chromatin immuno-precipitations |
WO2012050963A2 (en) * | 2010-09-29 | 2012-04-19 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Agents providing controls and standards for immuno-precipitation assays |
EP2859139B1 (en) * | 2012-06-06 | 2018-08-01 | The Trustees Of Princeton University | Dna barcoding of designer mononucleosome and chromatin array libraries for the profiling of chromatin readers, writers, erasers, and modulators thereof |
-
2015
- 2015-02-03 WO PCT/US2015/014296 patent/WO2015117145A1/en active Application Filing
- 2015-02-03 US US15/115,081 patent/US10732185B2/en active Active
- 2015-02-03 CN CN201580018619.8A patent/CN107002289B/zh active Active
- 2015-02-03 JP JP2016549801A patent/JP6985010B2/ja active Active
- 2015-02-03 EP EP15744035.5A patent/EP3102721B1/en active Active
- 2015-02-03 ES ES15744035T patent/ES2808651T3/es active Active
-
2019
- 2019-07-01 JP JP2019122877A patent/JP2019176878A/ja active Pending
-
2020
- 2020-06-19 US US16/906,513 patent/US11965890B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017506073A5 (ja) | ||
Sun et al. | Detect accessible chromatin using ATAC-sequencing, from principle to applications | |
Mouliere et al. | Detection of cellâfree DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients | |
Fischer et al. | Gelâaided sample preparation (GASP)âA simplified method for gelâassisted proteomic sample generation from protein extracts and intact cells | |
Shi et al. | Size profile of cell-free DNA: A beacon guiding the practice and innovation of clinical testing | |
CA2809282C (en) | Mesothelioma biomarkers and uses thereof | |
Arentz et al. | State of the art of 2D DIGE | |
KR101658347B1 (ko) | íì ë°ìŽì€ë§ì»€ ë° ê·žê²ë€ì ì©ë | |
JP2019176878A (ja) | ïœïœâèçœè³ªè€åäœã®çµæç© | |
De Ceuleneer et al. | In vivo relevance of citrullinated proteins and the challenges in their detection | |
Fabris et al. | Elucidating the higherâorder structure of biopolymers by structural probing and mass spectrometry: MS3D | |
EP2494065A1 (en) | Means and methods for non-invasive diagnosis of chromosomal aneuploidy | |
WO2009047526A1 (en) | Use of aptamers in proteomics | |
TW201639968A (zh) | è¡æŒ¿ç²ç·é«ïœïœïœåæä¹æçš | |
Di Meo et al. | Searching for prognostic biomarkers for small renal masses in the urinary proteome | |
Qi et al. | Proteogenomic analysis unveils the HLA class I-presented immunopeptidome in melanoma and EGFR-mutant lung adenocarcinoma | |
Mustafa et al. | Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients | |
van Der Pol et al. | Realâtime analysis of the cancer genome and fragmentome from plasma and urine cellâfree DNA using nanopore sequencing | |
Su et al. | Identification of splice variants and isoforms in transcriptomics and proteomics | |
Percy et al. | Multiplexed panel of precisely quantified salivary proteins for biomarker assessment | |
Lyons et al. | Peptidomic approaches to study proteolytic activity | |
Tang et al. | neoantigenR: an annotation based pipeline for tumor neoantigen identification from sequencing data | |
Che et al. | Expanded knowledge of cell-free DNA biology: Potential to broaden the clinical utility | |
Reilly et al. | Variant biomarker discovery using mass spectrometry-based proteogenomics | |
Mahgoub et al. | Dual histone methyl reader ZCWPW1 Facilitates repair of meiotic double strand breaks |